Managing catastrophic medical claims -prescription drug trends
Contenido multimedia no disponible por derechos de autor o por acceso restringido. Contacte con la institución para más información.
| Tag | 1 | 2 | Valor |
|---|---|---|---|
| LDR | 00000cab a2200000 4500 | ||
| 001 | MAP20190020879 | ||
| 003 | MAP | ||
| 005 | 20190709110311.0 | ||
| 008 | 190705e20190107usa|||p |0|||b|eng d | ||
| 040 | $aMAP$bspa$dMAP | ||
| 084 | $a7 | ||
| 100 | 1 | $0MAPA20190009331$aTroutman, Mark | |
| 245 | 0 | 0 | $aManaging catastrophic medical claims -prescription drug trends$c Mark Troutman, Larry P. Jackson |
| 300 | $a5 p. | ||
| 520 | $aThe major impact trend on catastrophic medical claims is specialty pharmacy developments in biosimilars, orphan drugs, and breakthrough therapies. This increasing pipeline of new specialty drugs and targeted therapies results from several market trends. Pharmaceutical manufacturers continue their direct-to-consumer advertising to increase consumer awareness. Increased utilization naturally occurs due to the aging population and trend toward outpatient health care, as well as new and more aggressive drug treatment plans. This situation creates a pushpull conflict between supplier and payer as suppliers push for solutions at highest cost to increase margin and payers push for solutions and lowest cost to increase bottom line. | ||
| 650 | 4 | $0MAPA20080567118$aReclamaciones | |
| 650 | 4 | $0MAPA20080606633$aIndustria farmacéutica | |
| 700 | 1 | $0MAPA20080195519$aJackson, Larry P. | |
| 773 | 0 | $wMAP20190020794$tContingencies : American Academy of Actuaries$dWashington : American Academy of Actuaries, 2019-2024$g07/01/2019 Año 2019 - January-February , p. 38-42 |